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Cyclooxygenases (particularily Cox-2) are involved in carcinogenesis and metastatic cancer progression. The expression profiles of
the cyclooxygenases and the roles they play in established tumours of similar stage remains unclear. We report that Cox-1 and Cox-2
expression is highly variable in Dukes’ C tumours, and changes in Cox-1 expression may be of importance.
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Colorectal cancer is the third most common cancer in the Western
world and despite advances in surgery, adjuvant therapies and
screening, little impact on the mortality rates has been seen (Jemal
et al, 2003). A greater understanding of the molecular mechanisms
underlying carcinogenesis and progression is leading to novel
treatment strategies.
Cyclooxygenases (Cox) are responsible for the metabolism of
arachidonic acid into prostaglandins (Church et al, 2003). Two
isoforms exist, termed Cox-1 and Cox-2 (Vane, 1971; Xie et al,
1991). Increased expression of Cox-2 has been implicated in
carcinogenesis and metastatic progression in many forms of
human cancer (Church et al, 2003). For example, increased
expression of Cox-2 protein has been shown to correlate with
tumour invasiveness and metastasis (Chen et al, 2001). In addition,
100% of metastatic lesions had positive immunohistochemical
staining for Cox-2 vs 72% of primary tumours (Zhang and Sun,
2002). Cox-2 inhibitors are now being evaluated as adjuncts to
chemotherapy for colon cancer (Blanke, 2002; Blanke and
Masferrer, 2003).
Initial evidence with regard to the expression of Cox-1 suggested
a minimal role in colonic neoplasia, with several studies
demonstrating minimal expression of Cox-1 with little variability
in polyps and established tumours (Eberhart et al, 1994; Sano et al,
1995). More recent evidence suggests that Cox-1 expression and
activity may have a role to play in the carcinogenic process
(Takeda et al, 2003). For example, reduced polyp formation was
seen in MIN mice lacking a functional Cox-1 gene (Chulada et al,
2000) and Cox-1 expression may promote carcinogenesis in lung
and gynaecological tissues, both synergistically with and indepen-
dently of Cox-2 (Hasturk et al, 2002; Sales et al, 2002; Gupta et al,
2003). We used real time PCR to investigate Cyclooxygenase 1 and
2 expression profiles in invasive colonic tumours. Our aims were
to define cyclooxygenase expression patterns in established
colorectal tumours compared to adjacent normal mucosa and
correlate this with clinicopathological variables and patient
outcome.
MATERIALS AND METHODS
Patients
In total, 51 stage III (Dukes’ C) colorectal cancer patients had
tumour and adjacent normal bowel mucosa samples collected at
the time of surgical resection by The Siteman Cancer Center Tissue
Procurement Core. The median age of these patients was 68 (range
39–96 years). All samples were snap frozen and stored at  801C
until used for RNA extraction. In total, 29 patients (56.9%) were
male. Approval for this study, including the genomic analysis of
the tissue samples, was obtained from the Washington University
in St Louis Human Studies Committee. All patients gave informed
consent. Clinical data were collected prospectively and used to
compare expression with tumour differentiation, anatomic loca-
tion (either left or right colon), survival, recurrence (both
metastatic and local recurrence), patient gender and age.
RNA extraction and real time PCR for cyclooxygenases
The TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA, USA) was
used for RNA extraction from the paired tumour and normal
mucosa. Areas of high cellularity on light microscopy (median
86%, range 65–95%) were chosen from each tissue sample. RNA
was quantified and assessed for purity by measurement of OD260
and OD280 using a UV fiberoptic spectrophotometer (Nanodrop
Technologies, Rockland, DE, USA) and was qualitatively assessed
by measurement of relative 28S and 18S ribosomal band intensities
using a Bioanalyzer and RNA NanoChip capillary gel electrophor-
esis assay (Agilent Technologies, Palo Alto, CA, USA). RNAs were
reverse-transcribed into cDNA samples using Superscript II
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primers
and probes for the Real Time PCR for Cox-1 and Cox-2 RNA were
designed using the Primer Express Software (ABI, Foster City, CA,
USA) (Table 1). The probe and primer sets were synthesised by
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lIntegrated DNA Technologies (Coralvile, IA, USA). The relative
RNA quantitation was assessed by Taqman real time PCR using an
ABI PRISM 7700 analyser (Applied Biosystems, Foster City, CA,
USA). All real time PCR assays were performed in triplicate.
Measurement of relative RNA expression levels
The relative expression levels were calculated using the modified
comparative CT method (Pfaffl, 2001). The PCR efficiencies were
calculated from standard curves using the formula E¼10[ 1/
slope] where E is the efficiency and slope is the slope of the
standard curve. Standard curves for the reference and cycloox-
ygenase genes constituted separate experiments using pooled
colorectal cancer RNA samples (data not shown). The APP gene
was used as the internal reference. The relative expression level of
the RNA for each Cox gene was normalised to the APP gene and to
one of all of the 102 tissue samples. The calibrator sample chosen
was that which had the maximum CT value, that is, the lowest
expression level. The normalised relative expression levels for each
gene was calculated using the following formula (Pfaffl, 2001):
E
DCT targetðcalibrator sampleÞ
target
E
DCT referenceðcalibrator sampleÞ
reference
where Etarget is the real-time PCR frequency of the target gene
transcript and Ereference is the real time PCR efficiency of the
reference gene transcript.
Statistics
Statistical analyses were performed using GraphPad InStat version
3.05 for GraphPad Software (San Diego, CA USA). Wilcoxon
matched pairs test and Spearman’s Rank Correlation coefficient
were used to evaluate the differences seen in expression levels of
the Cox enzymes between the samples. Kruskal–Wallis Test
(Nonparametric ANOVA) and Mann–Whitney U test was used to
compare cyclooxygenase expression and clinical and pathological
variables. Kaplan–Meier analyses were carried out when compar-
ing survival times. The P-values of o0.05 were considered to
be significant.
RESULTS
Substantial variation in the expression of Cyclooxygenase 2 mRNA
was observed in normal mucosa (33-fold) and tumour tissues (51-
fold). Variable Cox-1 expression was also seen in normal mucosa
(68-fold) and tumour (40-fold). Cox-2 was significantly upregu-
lated in the tumour samples compared to paired mucosal tissues
(median tumour:normal ratio¼1.54, range 0.20–8.96, P¼0.012,
Figure 1B). In contrast, tumour Cox-1 expression was significantly
lower than normal mucosal samples (median tumour:normal
ratio¼0.48, range 0.01–2.85, Po0.0001, Figure 1A). The expres-
sion levels of each enzyme in normal mucosa also correlated to the
expression seen in paired malignant mucosa (Cox-1, rs¼0.63,
Po0.0001; Cox-2, rs¼0.33, P¼0.008).
Cyclooxygenase-2 expression in tumour tissues did not correlate
with disease recurrence (P¼0.16), tumour differentiation
(P¼0.26), gender (P¼0.2), age 470 (P¼0.06), or site of tumour
(P¼0.84). Cox-1 expression similarly did not show any signifi-
cantly different expression in tumour or normal mucosa in
relation to these clinicopathological variables.
The relationships between Cox-1 and Cox-2 were also examined
(Figure 3A and B). In normal tissue a linear relationship could be
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Figure 1 Comparison of variations in expression of Cox 1 (A) and Cox
2( B) paired normal mucosa and tumour tissue samples. Horizontal lines
represent the mean for each population.
Table 1 RT–PCR probes for Cox-1, Cox-2 and the reference gene
APP. The fluorophores FAM, JOE, TAMRA were used, as indicated
Gene Primer Primer or probe sequence
Cox-1 Probe 50-FAM/CCTTCCATCCGGTGGCCTATTCCA/36-TAMRA
Forward
primer
50-CTGCCCTCCTCAAGACTTTAGCTT
Reverse
primer
50-TCCAACTGATTTAAGCAAAAGAGGAAT
Cox-2 Probe 50-FAM/AATCAAGCCTGGCTAGCATGCTG/36-TAMRA
Forward
primer
50-TGAAGCCAATTCAGTAGGTGCAT
Reverse
primer
50-ATCGCTAAAAGAAAAGAAAAGGA
APP
reference
gene
Probe 50-JOE/AGTTCAGCCTGGACGATCTCCAGCC/TAMRA
Forward
primer
50-CTCATGCCATCTTTGACCGA
Reverse
primer
50-GGGCATCAACAGGCTCAACT
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2¼0.32).
However this relationship was clearly not maintained in the
tumour tissues (Figure 3B, r
2¼0.003) with an increased expression
of Cox-2 protein relative to Cox-1 expression.
Patients were divided into high or low expression groups using
the median expression values for each cyclooxygenase gene. No
significant differences in cancer-specific survival were seen using
Cox-1 expression in normal (P¼0.26) or malignant tissues
(P¼0.36). Cox-2 expression in the tumour did not correlate with
survival (P¼0.85, Figure 2A) but patients expressing high levels of
Cox-2 in the normal mucosa appeared to have a survival advantage
(P¼0.02; Figure 2B).
DISCUSSION
Cox-1 and Cox-2 expression seen in normal and malignant mucosa
showed wide variation, even in the context of patients with the
same clinical disease stage. The validity of such variation could be
confirmed with immunohistochemistry but the recovery of tissue
slides for inclusion in this pilot study was not possible. The
previously reported immunohistochemical studies have also
shown large differences in the staining intensity, and the numbers
of cells expressing the Cox-2 protein (Hao et al, 1999; Masunaga
et al, 2000; Cianchi et al, 2001). Our RNA expression data highlight
such previously observed variability. These and other studies have
been able to show that such elevated expression of Cox-2
correlated with clinicopathological variables. However, thresholds
for positivity in these studies were low, including cells weakly
stained, and sections with less than 10% of epithelial cell
population deemed to be positive (Cianchi et al, 2001; Zhang
and Sun, 2002). In addition, these studies utilised samples obtained
across various disease stages. The increased expression of
cyclooxygenase-2 mRNA in tumour in this study is consistent
with these previous studies (Church et al, 2003).
A direct molecular basis for the upregulation of Cox-2 in polyps
and cancer is still poorly defined. However, one mechanism may
be the clonal expansion of tumour cells that express Cox-2. Such
increased expression seems to increase tumour angiogenesis and
decrease cellular apoptosis, leading to improved overall cellular
viability compared to tumours not aberrantly expressing this
protein (Church et al, 2003).
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Figure 2 Relationship between patient survival and Cox-2 expression in
tumour tissues (A) and normal mucosa (B).
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Figure 3 Relationship between Cox-1 and Cox-2 expression in normal
mucosa (A) and tumour (B).
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or disease recurrence in patients expressing high levels of Cox-2 in
tumour. This may reflect the fact that our samples are from a well-
defined stage of disease progression, that is, Dukes’ C tumours.
Previously, it has been suggested that Cox-2 expression is
associated with poorer outcomes; however, these studies compared
expression across clinical disease stages and were not able to
demonstrate any predictive potential independent of Dukes’ stage
(Sheehan et al, 1999; Masunaga et al, 2000). Patients with a high
level of Cox-2 expression in the normal mucosa did seem to have
survival advantage. The reasons for this observation are not easily
explained and conflicts with some previous studies that examined
the expression of the cyclooxygenases in the malignant tumour
(Church et al, 2003).
The expression levels of Cox-1 also demonstrated considerable
variation in RNA expression in normal and malignant tissues. This
contrasts with the previously accepted opinion that Cox-1 exists as
a house keeping gene, which is not subject to variable expression
(Sano et al, 1995). More recent evidence suggests that Cox-1 is
inducible and can be upregulated in malignant tissues (Sales et al,
2002; Gupta et al, 2003). We have shown that Cox-1 seemed to be
downregulated in colorectal tumour specimens. Indeed, a syner-
gistic relationship of the cyclooxygenases in the early stages of
carcinogenesis has been suggested, with Cox-1 having a role
initially followed by a rise in Cox-2 expression as the malignant
process continues (Takeda et al, 2003). Our data confirm an
altered regulation of Cox-1 expression between normal and
malignant tissues, consistent with such suggestions. It has also
been suggested that the increases of Cox-2 expression and the
tissue-specific prostaglandin E Synthetase often seen in malignant
tissue may be dependent on the expression of Cox-1, at least
initially (Takeda et al, 2003). There is emerging evidence that Cox-
1 may have a role to play in carcinogenesis in other solid tumours
such as ovarian (Gupta et al, 2003) and skin cancer (Tiano et al,
2002). This may mean that the nonspecific cyclooxygenase
inhibitors, such as sulindac and aspirin, may be more important
agents in the prevention of colonic polyps, if compared to the Cox-
2 specific inhibitors, such as celecoxib and rofecoxib, which are
currently being studied in this context. However, the reduction in
Cox-1 expression in more advanced disease supports the view that
as additions to adjuvant therapy regimes specific Cox-2 inhibitors
should be more effective.
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